XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 30.02

+0.7%

11:03 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LarryS who wrote (16018)	8/31/2002 4:18:02 PM
From: aknahow	Read Replies (1) of 17367

Various deal could at least extend the date by which Xoma needs new cash. A $50 million financing deal, over a 3 year period, is already in place with MLNM but of course it means dilution. Other licensing deals be they for expression technology, phage technology or human engineering can bring in cash. Neuprex milestones could also mean cash if the BAX agreement really is viable. Not sure at the moment what Baxter's intentions are. I felt that a sepsis trial would be complicated and take a long time to design well so I did not think Baxter was stalling. I am no longer as confidant that this is the case. Somatagen was merged into Baxter. What happened to the technology? ALLP looked like they had something of value but they too have been stiffed by Baxter. So as of now, if anyone cared, I would say don't partner with Baxter. Ya, Cacaito, duele pero, tal vez tu tennia razon!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next